Not Yet RecruitingPhase 1LSD

Shortened LSD Intervention for Major Depressive Disorder

Sponsored by Johns Hopkins University

NCT ID
NCT07503002
Target Enrollment
10 participants
Start Date
2026-07-01
Est. Completion
2027-12-01

About This Study

The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.

Conditions Studied

Major Depression ModerateMajor Depression SevereMajor Depression

Interventions

  • LSD
  • Risperidone

Eligibility

Age:21 Years - 70 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria:

* Have given written informed consent
* Meet DSM-5 criteria for MDD
* MADRS \>= 28 at screening Can read, write, and speak English fluently
* Be judged by study team clinicians to be at low risk for suicidality

Exclusion Criteria:

* Women who are pregnant, nursing, or not practicing an effective means of birth control
* Cardiovascular conditions: hypertension with resting blood pressure systolic \>139 or diastolic \>89, angina, heart rate \> 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc \> 450), TIA in the last 6 months stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy
* Epilepsy
* Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
* Currently taking antipsychotics, or MAO inhibitors
* Patients taking antidepressant medications and unable to taper
* Moderate or strong CYP2D6 inhibitor antidepressants must undergo a washout period of 4 weeks or five half-lives prior to treatment
* Currently taking CYP2D6 inhibitor other than an antidepressant that will be tapered
* Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UGT1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag
* Have a seizure disorder, multiple sclerosis, history of significant head trauma, CNS tumor, movement disorders or any neurodegenerative condition
* Morbidly obese (\>100 lbs. above ideal body weight, or BMI \>=40, or BMI \>=35 with high blood pressure or diabetes)
* Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal
* Body weight \< 45 kg
* Significant acute adverse reaction (e.g., dystonia) to an antipsychotic
* Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (including substance-induced), Bipolar I or II Disorder or Major
* Depression with psychotic features
* Have a first degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or Bipolar I Disorder.

Study Locations (1)

Johns Hopkins Center for Psychedelic and Consciousness Research
Baltimore, Maryland, United States

Interested in this trial?

Contact the study team to learn more about eligibility and enrollment.

Matthew Nielsen, BA
CONTACT
917-991-0642mnielse7@jh.edu
View on ClinicalTrials.gov
Data Source
ClinicalTrials.gov

Last updated from source